About the ABPI

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

  1. Erik Nordkamp has been Managing Director at Pfizer UK since March 2015 and originally joined Pfizer in 2010, serving as Head of Strategy for Primary Care Europe and Canada at Pfizer in the UK. He also served as President of PhRMA Innovation, the global trade association for the pharmaceutical industry, where he led the transformation of the forum, positioning it as the main representative body for the innovative pharmaceutical industry in Greece. He has been a Non-Executive Director of King's College Hospital NHS Foundation Trust since January 2016 and is currently Chair of the American Pharmaceutical Group.
  2. Haseeb Ahmad joined Novartis as Managing Director, UK & Ireland for Pharmaceuticals, and Country President UK, in February 2017, and was elected to the ABPI Board shortly after. In his prior role with MSD, as Managing Director for Greece, he delivered significant growth through a period of major economic upheavals, he also led the relevant industry association, the American Chamber of Commerce Pharma Group. During his twenty-year career, Haseeb has held progressively senior in-country and above-country roles in Strategy, Operations, Sales and Marketing.

Media enquiries


+44 (0) 20 7747 7147​​